We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Grassley's Concerns Play no Role in CDER Reorganization, FDA Says
Grassley's Concerns Play no Role in CDER Reorganization, FDA Says
May 19, 2006
The FDA’s CDER reorganization plans are not an effort to address lawmakers’ concerns about a lack of independence — but rather an attempt to further the agency’s Critical Path initiative and improve its drug safety efforts, an FDA official says.